Literature DB >> 31245084

Is there a role for upfront surgery in patients with N2 disease and good prognostic features?

Candice Lee1, David A Guel1, Benny Weksler1.   

Abstract

Entities:  

Year:  2019        PMID： 31245084      PMCID： PMC6560617          DOI： 10.21037/jtd.2019.03.68

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

Authors:  Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

2.  Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.

Authors:  F Andre; D Grunenwald; J P Pignon; A Dujon; J L Pujol; P Y Brichon; L Brouchet; E Quoix; V Westeel; T Le Chevalier
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

3.  Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.

Authors:  Zuen Ren; Shijie Zhou; Zhidong Liu; Shaofa Xu
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

4.  Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe.

Authors:  Masayoshi Inoue; Noriyoshi Sawabata; Shin-ichi Takeda; Mitsunori Ohta; Yuko Ohno; Hajime Maeda
Journal:  J Thorac Cardiovasc Surg       Date:  2004-04       Impact factor: 5.209

5.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

6.  Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.

Authors:  Steven M Keller; Mark G Vangel; Henry Wagner; Joan H Schiller; Arnold Herskovic; Ritsuko Komaki; Randolph S Marks; Michael C Perry; Robert B Livingston; David H Johnson
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

7.  Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

Authors:  Herbert Decaluwé; Paul De Leyn; Johan Vansteenkiste; Christophe Dooms; Dirk Van Raemdonck; Philippe Nafteux; Willy Coosemans; Toni Lerut
Journal:  Eur J Cardiothorac Surg       Date:  2009-06-06       Impact factor: 4.191

8.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

9.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.

Authors:  Stefan Walbom Harders; Hans Henrik Madsen; Karin Hjorthaug; Anne Kirstine Arveschoug; Torben Riis Rasmussen; Peter Meldgaard; Johanne Andersen Hoejbjerg; Hans Kristian Pilegaard; Henrik Hager; Michael Rehling; Finn Rasmussen
Journal:  Cancer Imaging       Date:  2014-06-03       Impact factor: 3.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.